Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BGM GroupBGM -0.38%36 Days Payable is 69.02 as of Sep. 2025, which is 86% above its 10-year median of 37.15. GuruFocus rates BGM with a GF Score™ of 36/100 and a GF Value™ of $0.25 (Fairly Valued). The stock has 7 warning signs investors should review. Among 923 Drug Manufacturers companies, BGM Group ranks worse than 57.96% on this metric.
BGM Group's average Accounts Payable for the
six
months ended in Sep. 2025 was $7.49 Mil. BGM Group's Cost of Goods Sold for the
six
months ended in Sep. 2025 was $19.81 Mil.
Hence, BGM Group's Days Payable for the
six
months ended in Sep. 2025 was 69.02.
The historical rank and industry rank for BGM Group's Days Payable or its related term are showing as below:
BGM'
s Days Payable Range Over the Past 10 Years
Min: 34.13 Med: 37.15 Max: 89.29
Current: 73.55
During the past 9 years, BGM Group's highest Days Payable was 89.29. The lowest was 34.13. And the median was 37.15.
BGM's Days Payable is ranked worse than 57.96% of 923
companies
in the Drug Manufacturers industry
Industry Median: 88.75
vs BGM: 73.55
BGM Group's Days Payable
increased
from Sep. 2024 (63.08) to Sep. 2025 (69.02).
It may suggest that BGM Groupdelayed paying its suppliers.
The historical data trend for BGM Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BGM Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BGM Group Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BGM Group's Days Payable distribution charts can be found below:
* The bar in red indicates where BGM Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BGM Group's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGM Group (BGM) has a Days Payable of 69.02 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BGM Group and its competitors. This is 86% above median its historical median of 37.15. Over the past decade, BGM Group's Days Payable has ranged from 34.13 to 89.29. According to the industry distribution chart, BGM Group ranks #535 out of 923 companies in the Drug Manufacturers industry, placing it in the top 58%.
Is BGM Group's Days Payable too high?
BGM Group's current Days Payable of 69.02 is 86% above median its 10-year median of 37.15. Over the past 10 years, this metric has ranged from a low of 34.13 to a high of 89.29. The Drug Manufacturers industry median Days Payable is 88.75. BGM Group's value of 69.02 is 22.2% below this industry median. Based on the distribution chart, BGM Group ranks #535 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, BGM Group has a GF Score™ of 36/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BGM Group's Days Payable compare to CPIX and ADCT?
According to the Drug Manufacturers industry distribution chart, BGM Group ranks #535 out of 923 companies for Days Payable. This places BGM Group in the lower half of its industry. The industry median Days Payable is 88.75. BGM Group's value of 69.02 is 22.2% below this benchmark. Historically, BGM Group's own Days Payable has ranged from 34.13 to 89.29 over the past decade. While the company's 10-year median is 37.15 vs. the industry median of 88.75, BGM Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.75, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BGM Group's current Days Payable of 69.02 is 22.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BGM Group and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BGM Group's current Days Payable is 69.02, which is 86% above median its own 10-year median of 37.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BGM Group stock overvalued right now?
Based on GuruFocus' analysis, BGM Group (BGM) is currently considered Fairly Valued. The stock's GF Value™ is $0.25, compared to a current price of $0.26 — trading 4.9% above its estimated fair value. The current Days Payable is 69.02, which is 86% above median its 10-year median of 37.15 and 22.2% below the Drug Manufacturers industry median of 88.75. BGM Group's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BGM Group (BGM), the current Days Payable is 69.02 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BGM Group (BGM) Overvalued in 2026?
Based on GuruFocus' analysis, BGM Group stock appears to be overvalued.
The current stock price of $0.26 is trading 4.9% above its estimated GF Value™ of $0.25.
GuruFocus considers BGM Group to be Fairly Valued.
Key valuation signals for BGM:
Days Payable: 69.02 (86% above median its 10-year median of 37.15)
GF Value™: $0.25 vs. price of $0.26 (4.9% above fair value)
Industry Position: 22.2% below the Drug Manufacturers median (#535 of 923)
No single metric tells the full story. See the BGM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
36GF Score
Get the complete analysis for BGM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGM has been successfully added to your 
